Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

ShangPharma Buys Charles River’s Shanghai Lab

publication date: Oct 24, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
ShangPharma acquired the Shanghai research facility formerly owned by Charles River Labs. The purchase will allow ShangPharma’s main subsidiary, Shanghai ChemPartner, to expand its GLP tox study capacity. The lab comprises 31,990 square feet of in-vivo research facilities, which were designed for GLP tox studies, plus another 13,885 square feet of lab and office space. More details....

Stock Symbols: (NYSE: SHP) (NYSE: CRL)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...